RecruitingPhase 3NCT05756179

Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis

Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis


Sponsor

Alexandria University

Enrollment

80 participants

Start Date

Jul 18, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Evaluating the effect of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis


Eligibility

Min Age: 19 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether diosmin and hesperidin — natural plant-based compounds often used for vein health — can reduce inflammation and improve symptoms in people with mild to moderate rheumatoid arthritis (RA), a chronic joint disease caused by the immune system attacking joints. **You may be eligible if...** - You have been diagnosed with rheumatoid arthritis with mild to moderate disease activity - You are older than 18 years **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have liver or kidney disease, or other significant inflammatory conditions - You are currently taking TNF-alpha blockers or IL-1 inhibitors (biologics for RA such as adalimumab, anakinra, etc.) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDiosmin and Hesperidin Combination

Diosmin 450 mg and Hesperidin 50 mg Combination


Locations(1)

Alexandria university hospital

Alexandria, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05756179


Related Trials